Georgia's Online Cancer Information Center

Find A Clinical Trial

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Status
Closed
Cancer Type
Colon/Rectal Cancer
Unknown Primary
Trial Phase
Phase III
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT04793958
Protocol IDs
849-010 (primary)
NCI-2021-03009
KRYSTAL-10
Study Sponsor
Mirati Therapeutics

Summary

Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of
MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line
treatment setting in patients with CRC with KRAS G12C mutation.

Eligibility

  1. Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue.
  2. Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.